title: Acyclovir therapy in prevention of recurrent herpetic keratitis following penetrating keratoplasty.
abstract: OBJECTIVE
  To compare systemic vs topical acyclovir therapy for the prevention of recurrence of herpetic keratitis following penetrating keratoplasty (PK).
  
  
  METHODS
  A retrospective observational study.
  
  
  METHODS
  Patients who underwent PK for herpetic eye disease (HED) and prophylactically received acyclovir therapy postoperatively, either systemically (26 eyes) or topically (29 eyes), were analyzed. The main parameters evaluated were recurrence of herpetic keratitis, graft rejection, visual acuity, and graft survival rate.
  
  
  RESULTS
  Mean average follow-up period was 24.7 +/- 3.6 months and 23.5 +/- 2.3 months in the systemic and topical group, respectively (P = 0.73). The average duration of prophylactic antiviral therapy in systemic group was 16.1 +/- 4.8 months and in topical group was 15.1 +/- 3.5 months (P = .59). Recurrence of herpetic keratitis was seen in 12% in the systemic group compared to 55% in the topical group (P < .001). More eyes in topical group 15 (52%) had rejection episodes than in the systemic group 5 (19%) (P < .001). A best-corrected visual acuity of > or = 20/40 was achieved in 31% and 7% eyes in the systemic and topical group, respectively, at the end of two years (P = .002). The clear graft survival rate in the systemic and topical acyclovir receiving group was 96.2% vs 86.2% at 12 months, and 88.5% vs 65.5% at 24 months, respectively.
  
  
  CONCLUSIONS
  Systemic acyclovir is more effective than topical acyclovir in achieving better graft outcomes after PK for HED.
authors.affiliation: Centre for Eye Research Australia, University of Melbourne, 32 Gisborne Street, East Melbourne, Victoria 3002, Australia.
authors.forename: Sudipta
authors.initials: S
authors.lastname: Ghosh
authors.forename: Vishal
authors.initials: V
authors.lastname: Jhanji
authors.forename: Ecosse
authors.initials: E
authors.lastname: Lamoureux
authors.forename: Hugh R
authors.initials: HR
authors.lastname: Taylor
authors.forename: Rasik B
authors.initials: RB
authors.lastname: Vajpayee
mesh_terms: D000212:Acyclovir / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006085:Graft Survival; D006801:Humans; D016849:Keratitis, Herpetic / Q000517:prevention & control* / Q000601:surgery*; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D014792:Visual Acuity
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir